Marinus Pharma (MRNS) Plans Public Offering of Common Stock and Concurrent Private Placement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Marinus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Concurrent Private Placement
December 10, 2019 4:25 PM ESTRADNOR, Pa., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS), (Marinus or the Company) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares in the offering are to be sold by Marinus. Marinus also expects to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the number of shares to be issued and sold in the public offering. The offering is subject to market conditions, and there can be no assurance... More
